Endocrine Abstracts

Background: Magnesium oxide is widely used for constipation and antacid. Some studies showed another antacid, proton pump inhibitor increased the risk of fracture. The association between laxative and the risk of fracture was limited. Our study aimed to evaluate the association between: usage of Magnesium oxide and fracture.

Design: Nationwide population-based retrospective cohort study.

Setting: Taiwan’s National Health Insurance Research Database.

Participants: Individuals with usage (n=3,273) and without usage (n=13,092) of Magnesium oxide.

Measurement: Individuals with and without Magnesium oxide were matched 1:4 for age, sex, and index year. Those with fracture were further divided into hip fracture, vertebral fracture and other fracture. Incidences and hazard ratios (HR) for risks of developing fracture were calculated using Cox proportional hazard regression models.

Results: During mean follow-up of 4.8years, 567 participants in the usage cohort and 1859 participants in the non-usage cohort developed fracture events. Having usage of Magnesium oxide was significantly associated with risk of developing fracture events (adjusted HR (aHR) =1.2, 95% confidence interval (CI) =1.09–1.32, P<0.001, hip fracture: aHR =2.14, 95% CI =1.63–2.81, P<0.001, vertebral fracture: aHR =1.68, 95% CI =1.38–2.04, P<0.001)). But, there was no associated with risk of developing other fracture.

Conclusion: Magnesium oxide was independently associated with increased risks of fracture, especially over hip and vertebral fracture.